Close Menu

NEW YORK — Solvd Health said on Monday that it has received CE marking for its genetic risk assessment test for opioid use disorder.

According to the Carlsbad, California-based company, the test analyzes a cheek swab sample for 15 genetic variants that have been implicated in the brain's reward pathway and can help guide the use of oral opioids for acute pain.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.